Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2024-04-16 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
2023年度独立董事述职报告（潘鹰）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告（潘鹰）" which translates to "2023 Annual Independent Director's Work Report (Pan Ying)". It details the independent director's attendance at board meetings, opinions on various board resolutions, communication with internal audit and accounting firms, and efforts to protect investor rights. The content focuses on the independent director's duties and activities during the year 2023. It is not a full annual report, audit report, or financial statement, but rather a management-related report on the independent director's work and governance oversight. This fits best under Board/Management Information (MANG) as it relates to board member activities and governance roles. The document length is 3646 characters, which is relatively short and consistent with a report or statement rather than a full financial report. Therefore, the classification is MANG with high confidence.
2024-04-16 Chinese
独立董事候选人声明与承诺（胥兴军）
Board/Management Information Classification · 95% confidence The document is a statement and commitment by an independent director candidate for Chengdu Oukang Pharmaceutical Co., Ltd. It details the candidate's qualifications, compliance with relevant laws and regulations, and declarations of independence. There is no financial data, no report or announcement of financial results, no voting results, no management changes, and no regulatory filings of other types. The document is a formal declaration related to board/management information, specifically about a director candidate's qualifications and commitments. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on the candidate's statement, not a full report or announcement of a meeting or vote.
2024-04-16 Chinese
关于成都欧康医药股份有限公司非经营性资金占用及其他关联资金往来情况专项审核说明
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核说明" (special audit explanation) regarding "非经营性资金占用及其他关联资金往来情况" (non-operating fund occupation and other related party fund transactions) for Chengdu Oukang Pharmaceutical Co., Ltd. It references the 2023 fiscal year and mentions an audit report with an unqualified opinion (无保留意见的审计报告) on the 2023 financial statements. The document includes a summary table of related party fund transactions and audit procedures performed by a registered CPA firm. This is a standalone audit-related report focusing on a specific aspect of the company's financials (non-operating fund occupation and related party transactions), not the full annual report or financial statements themselves. It is not a general regulatory announcement or a brief notice but a detailed audit explanation and opinion on a specific financial matter. Therefore, it fits the category of Audit Report / Information (AR). The document length (15,000 characters) and content support this classification with high confidence.
2024-04-16 Chinese
2023年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年度募集资金存放与实际使用情况的专项报告" which translates to "2023 Annual Report on the Storage and Actual Use of Raised Funds." It details the amount of funds raised through a public stock issuance, the timing of the funds received, the usage of these funds during the year, the balance remaining, and compliance with regulatory requirements. It includes detailed financial figures on the raised funds, their management, and usage progress, as well as verification opinions from a sponsoring institution and an accounting firm. The document is focused on the specific topic of fundraising and the use of those funds, which aligns with a Capital/Financing Update. The length is 4268 characters, which is substantial but not a full annual report or interim report. It is not a simple announcement or certification but a detailed report on fundraising usage. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-04-16 Chinese
拟续聘2024年度会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (audit firm) for the 2024 fiscal year. It details the background, qualifications, and independence of the audit firm, the audit fees, and the approval process by the board and audit committee. It does not contain any actual audit report, financial statements, or audit results. The document is relatively short (2722 characters) and serves as a formal announcement of the intention to reappoint the auditor, pending shareholder approval. Therefore, it is not an audit report itself but an announcement related to audit services. According to the classification rules, such announcements about audit firm appointments or reappointments fall under Regulatory Filings (RNS) as they do not contain substantive audit report content or financial data.
2024-04-16 Chinese
2023年年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as a "2023 Annual Equity Distribution Plan Announcement" from Chengdu Oukang Pharmaceutical Co., Ltd. It discusses the company's plan to distribute cash dividends for the fiscal year 2023, referencing the audited 2023 annual report but not containing the full report itself. It includes details on the dividend amount, board and supervisory committee approvals, company articles of association on profit distribution, and the process for shareholder approval. The document is relatively short (3452 characters) and primarily serves as an announcement of the dividend distribution plan rather than a full financial report. This fits the definition of a Notice of Dividend Amount (DIV) filing, which announces dividend amounts, payment dates, and related details for shareholders.
2024-04-16 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.